- cafead Apr 26, 2024 at 11:42: AM
via There are more than 50 glucagon-like peptide-1 receptor agonists (GLP-1RAs) in clinical development for Type 2 diabetes, obesity, or both.
Clinical trials on the efficacy and safety of these medicines and combination therapies involving them are ongoing, including cardiovascular outcome trials to prove further safety against cardiovascular events.
article source
Clinical trials on the efficacy and safety of these medicines and combination therapies involving them are ongoing, including cardiovascular outcome trials to prove further safety against cardiovascular events.
article source